DGX

$198.61

Market ClosedAs of Mar 17, 8:00 PM UTC

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$198.61
Potential Downside
7.8%
Whystock Fair Value$183.10
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDiagnostics & Research

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, a...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
22.72
Beta
Defensive asset. Lower volatility than the S&P 500.
0.63
Div Yield
Strong income play. Yield provides a meaningful total return floor.
173.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
14.75%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.80

Recent News

Simply Wall St.
Mar 17, 2026

A Look At Quest Diagnostics (DGX) Valuation After Recent Share Price Softness

Event overview and recent stock performance Quest Diagnostics (DGX) has been drawing attention after recent share price moves, with the stock down 0.4% over the past day and 1.3% over the past week, while remaining positive over the past 3 months and over the past year. See our latest analysis for Quest Diagnostics. Short term share price weakness contrasts with firmer momentum over longer periods, with the recent 3 month share price return of 11.35% and 1 year total shareholder return of...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

4 Outpatient Home Health Stocks Gaining Attention Amid Market Shifts

An aging population and rising AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, OPCH and ADUS stand to benefit.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 17, 2026

Guardant Health Touts Quest Deal for Shield, Guardant360 Growth and FDA Milestones at Leerink Conference

Guardant Health (NASDAQ:GH) executives highlighted new commercial initiatives for its Shield colorectal cancer screening test, continued growth drivers for its Guardant360 therapy selection franchise, and upcoming milestones tied to regulatory and reimbursement pathways during a conference discussio

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 16, 2026

Beat the Market the Zacks Way: IPG Photonics, Celanese, Costco in Focus

IPG Photonics has surged 43.1% since a Zacks Rank #1 upgrade, showcasing how the firm's stock-picking approach is beating a volatile market.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 12, 2026

Quest Diagnostics (DGX) Down 4.2% Since Last Earnings Report: Can It Rebound?

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.